Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NCT: NCT04446416 · COMPLETED
Brief Summary
This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients. The BEV is the best physician's choice of standard of care for rGBM after prior radiotherapy and temozolomide chemotherapy in the LinKou Chang Gung Memorial Hospital. Eligible patients will be enrolled through the process of informed consent.
Frequently Asked Questions
What is Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients?
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients is a clinical trial registered under NCT04446416. Current status: COMPLETED.
What is the status of NCT04446416?
The current status of NCT04446416 (Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients) is: COMPLETED.
When did Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients start?
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients started on 2020-07-21.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.